http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105250253-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105250253-B |
| titleOfInvention | Applications of the T0901317 as PARP1 inhibitor |
| abstract | The present invention relates to N (2,2,2 trifluoroethyls) N [4 [2,2,2 trifluoro 1 hydroxyl 1 (trifluoromethyl) ethyl] phenyl] benzsulfamide (being abbreviated as T0901317) is as 1 type poly ADP ribose synthetase inhibitors.Above-mentioned T0901317 belongs to the cytotoxicity that cholesterol analog has no usual tumour medicine or other 1 type poly ADP ribose synthetase inhibitors, it is contemplated that its safety.It can the extensive use as the treatment cholesterol related diseases such as drug of the diseases such as angiocardiopathy, tumour. |
| priorityDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.